Han-Yu Deng1,2, Xi Zheng2, Guha Alai1, Gang Li1, Jun Luo1, Ze-Guo Zhuo1, Yi-Dan Lin1. 1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. 2. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract
BACKGROUND: Whether tumor location has any impact on the survival of esophageal adenocarcinoma patients remains unclear. Therefore, we aimed to investigate the prognostic value of tumor location for esophageal adenocarcinoma based on the eighth edition of tumor-node-metastasis (TNM) staging system in Chinese patients for the first time. METHODS: We conducted a retrospective analysis of patients undergoing esophagectomy for esophageal adenocarcinoma in our department. We analyzed the data about demography, comorbidity, pathologic findings, surgical approach, adjuvant therapy, and survival time. Tumor location was categorized into two groups: adenocarcinomas at the esophagogastric junction (EGJ) and adenocarcinomas at other sites of the esophagus. Both univariate and multivariate analyses were applied. And propensity-score matched (PSM) analysis was also conducted for comparison. RESULTS: A total of 107 patients from January 2009 to December 2015 were involved in the analysis. The median follow-up time was 60.0 months and the median survival time of all those patients was 41.0 months. In the univariate analysis, adenocarcinomas in the EGJ (P=0.047), early pT stage (P=0.030), and moderate/well differentiation (P=0.022) were significantly correlated with better survival. Moreover, in the multivariate analysis, tumor site [hazard ratio (HR) =0.536; 95% confidence interval (CI) =0.300-0.958], pT stage (HR =0.298; 95% CI =0.124-0.717), and tumor differentiation (HR =0.437; 95% CI =0.238-0.802) were significant independent prognostic factors for overall survival of these esophageal adenocarcinoma patients. After the adjustment by PSM, patients with adenocarcinomas at the EGJ still yielded significantly longer survival than these with adenocarcinomas at other sites of the esophagus (P=0.039). CONCLUSIONS: Tumor location was an independent prognostic factor for esophageal adenocarcinoma based on the eighth edition of TNM staging system in Chinese patients. Therefore, different surgical therapeutic modalities may be applied for esophageal adenocarcinoma with different tumor locations.
BACKGROUND: Whether tumor location has any impact on the survival of esophageal adenocarcinoma patients remains unclear. Therefore, we aimed to investigate the prognostic value of tumor location for esophageal adenocarcinoma based on the eighth edition of tumor-node-metastasis (TNM) staging system in Chinese patients for the first time. METHODS: We conducted a retrospective analysis of patients undergoing esophagectomy for esophageal adenocarcinoma in our department. We analyzed the data about demography, comorbidity, pathologic findings, surgical approach, adjuvant therapy, and survival time. Tumor location was categorized into two groups: adenocarcinomas at the esophagogastric junction (EGJ) and adenocarcinomas at other sites of the esophagus. Both univariate and multivariate analyses were applied. And propensity-score matched (PSM) analysis was also conducted for comparison. RESULTS: A total of 107 patients from January 2009 to December 2015 were involved in the analysis. The median follow-up time was 60.0 months and the median survival time of all those patients was 41.0 months. In the univariate analysis, adenocarcinomas in the EGJ (P=0.047), early pT stage (P=0.030), and moderate/well differentiation (P=0.022) were significantly correlated with better survival. Moreover, in the multivariate analysis, tumor site [hazard ratio (HR) =0.536; 95% confidence interval (CI) =0.300-0.958], pT stage (HR =0.298; 95% CI =0.124-0.717), and tumor differentiation (HR =0.437; 95% CI =0.238-0.802) were significant independent prognostic factors for overall survival of these esophageal adenocarcinoma patients. After the adjustment by PSM, patients with adenocarcinomas at the EGJ still yielded significantly longer survival than these with adenocarcinomas at other sites of the esophagus (P=0.039). CONCLUSIONS: Tumor location was an independent prognostic factor for esophageal adenocarcinoma based on the eighth edition of TNM staging system in Chinese patients. Therefore, different surgical therapeutic modalities may be applied for esophageal adenocarcinoma with different tumor locations.
Authors: Harry H Yoon; Maliha Khan; Qian Shi; Stephen D Cassivi; Tsung-Teh Wu; J Fernando Quevedo; Patrick A Burch; Frank A Sinicrope; Robert B Diasio Journal: Mayo Clin Proc Date: 2010-12 Impact factor: 7.616
Authors: Bryan A Whitson; Shawn S Groth; Zhongze Li; Robert A Kratzke; Michael A Maddaus Journal: J Thorac Cardiovasc Surg Date: 2009-06-13 Impact factor: 5.209
Authors: Luis F Oñate-Ocaña; Gonzalo Milán-Revollo; Vincenzo Aiello-Crocifoglio; José F Carrillo; Dolores Gallardo-Rincón; Rocío Brom-Valladares; Roberto Herrera-Goepfert; Alfonso Dueñas-González Journal: Ann Surg Oncol Date: 2007-01-18 Impact factor: 5.344
Authors: Jessica M Leers; Steven R DeMeester; Nadia Chan; Shahin Ayazi; Arzu Oezcelik; Emmanuele Abate; Farzaneh Banki; John C Lipham; Jeffrey A Hagen; Tom R DeMeester Journal: J Thorac Cardiovasc Surg Date: 2009-07-14 Impact factor: 5.209
Authors: T W Rice; V W Rusch; C Apperson-Hansen; M S Allen; L-Q Chen; J G Hunter; K A Kesler; S Law; T E M R Lerut; C E Reed; J A Salo; W J Scott; S G Swisher; T J Watson; E H Blackstone Journal: Dis Esophagus Date: 2009 Impact factor: 3.429
Authors: Aaldert K Talsma; Chin-Ann J Ong; Xinxue Liu; Pieter van Hagen; Jan J B Van Lanschot; Huug W Tilanus; Richard H Hardwick; Nicholas R Carroll; Manon C W Spaander; Rebecca C Fitzgerald; Bas P L Wijnhoven Journal: World J Surg Date: 2014-01 Impact factor: 3.352
Authors: Zixian Jin; Jianfei Shen; Chunguo Wang; Dong Chen; Bo Zhang; Jian Zhang; Jaffer A Ajani; Jaafar Bennouna; Joseph Chao; Harry H Yoon; Hongyu Zhu; Yuhang Ruan; Chengchu Zhu; Anyi Xu Journal: Ann Transl Med Date: 2021-07